2010;170:1433 41. 436. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e531S 75S. 437. Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary a consensus document of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J. 2010;31:1311 8. 438. Deleted in press. 439. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. JAm Coll Cardiol. 2011;57:173 80. 440. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and under- going percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107 15. 441. Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assess- ment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577 85. 442. Follow-up to the January 26, 2009, early communication about an ongo- ing safety review of clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). US Food and Drug Administration. 2014. Available at: http://www.fda.gov/Drugs/ DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/ DrugSafetylnformationforHeathcareProfessionals/ucm190784.htm. Accessed June 12, 2014. 443. Marcucci R, Gori AM, Paniccia R, et al. Cardiovascular death and non- fatal myocardial infarction in acute coronary syndrome patients receiv- ing coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation. 2009;119:237 42. 444. 